GLUE (Monte Rosa Therapeutics) Tariff Resilience Score: 7/10 (As of Jul. 13, 2026)


GLUE Monte Rosa Therapeutics Inc GLUE
34 GF Score
Price $20.97
! 5 Warning Signs
View Full Analysis

What is Monte Rosa Therapeutics Tariff Resilience Score?

Monte Rosa Therapeutics GLUE -8.93% 34 Tariff Resilience Score is 7 as of Jul. 13, 2026. GuruFocus rates GLUE with a GF Score™ of 34/100. The stock has 5 warning signs investors should review. Among 1,370 Biotechnology companies, Monte Rosa Therapeutics ranks better than 90.36% on this metric.

Monte Rosa Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Monte Rosa Therapeutics has Monte Rosa Therapeutics has a moderate tariff resilience due to its focus on pharmaceuticals, which often enjoy tariff exemptions. Its global supply chain is diversified, reducing dependency on any single region.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Monte Rosa Therapeutics might have Highly Resilient.

Monte Rosa Therapeutics  (NAS:GLUE) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Monte Rosa Therapeutics Tariff Resilience Score Related Terms

GLUE vs SNDX, IOVA, TYRA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Monte Rosa Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monte Rosa Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Monte Rosa Therapeutics's Tariff Resilience Score falls into.


GLUE
34GF Score
Monte Rosa Therapeutics Inc GLUE
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Monte Rosa Therapeutics (GLUE) has a Tariff Resilience Score of 7 as of Jul. 13, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Monte Rosa Therapeutics ranks #132 out of 1370 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Monte Rosa Therapeutics' Tariff Resilience Score too high?
Monte Rosa Therapeutics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Monte Rosa Therapeutics' value of 7 is 75% above this industry median. Based on the distribution chart, Monte Rosa Therapeutics ranks #132 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Monte Rosa Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Monte Rosa Therapeutics' Tariff Resilience Score compare to SNDX and IOVA?
According to the Biotechnology industry distribution chart, Monte Rosa Therapeutics ranks #132 out of 1370 companies for Tariff Resilience Score. This places Monte Rosa Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Monte Rosa Therapeutics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monte Rosa Therapeutics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monte Rosa Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monte Rosa Therapeutics stock overvalued right now?
Monte Rosa Therapeutics (GLUE) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Monte Rosa Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current Tariff Resilience Score is 7 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monte Rosa Therapeutics Business Description

Address 321 Harrison Avenue, Suite 900, Boston, MA, USA, 02118
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
34GF Score

Get the complete analysis for GLUE

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.97
Price